|
시장보고서
상품코드
2078915
암 진단 시장 : 검사 유형별, 암 유형별, 최종사용자별 및 지역별Cancer Diagnostics Market, By Test Type, By Cancer Type, By End User, and by Region |
||||||
암 진단 시장은 2026년에 779억 5,000만 달러, 2033년까지 1,499억 7,000만 달러에 이를 것으로 예상됩니다. 또한, 2026-2033년 CAGR 9.8%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 779억 5,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 9.80% | 2033년 시장 규모 예측 : | 1,499억 7,000만 달러 |
암은 비정상적인 세포가 통제 불가능하게 증식하여 본래의 경계를 넘어 신체의 인접 부위로 침윤하거나 다른 장기로 전이함으로써, 체내의 거의 모든 장기나 조직에서 발생할 수 있는 광범위한 질환군입니다. 후자의 과정은 “전이”라고 불리며, 암으로 인한 사망의 주요 원인이 되고 있습니다. 신생물이나 악성 종양도 암의 일반적인 다른 이름입니다. 암 진단에 사용되는 종양 바이오마커 검사에는 전립선 특이 항원(PSA), 순환 종양 세포(CTC), 알파-태아단백(AFP) 검사, 췌장암 CA-19 검사, HER-2 검사, BRCA 검사, 폐암 ALK 검사, 암 태아 항원(CEA) 검사, EGFR 변이 검사, 그리고 RAS 변이 검사 등이 있습니다.
시장 역학
주요 시장 참여자들은 새로운 암 진단법 도입 등 유기적 성장 전략의 채택에 주력하고 있으며, 이것이 전 세계 암 진단 시장의 성장에 기여하고 있습니다. 예를 들어, 2020년 3월, 의료 기술 기업인 BD(벡톤 디킨슨 앤 컴퍼니)와 미국에 본사를 둔 비상장 임상 진단 기업인 BioMedomics는 혈액 내 항체를 검출하여 PARP 바이오마커에 대한 현재 또는 과거의 노출 여부를 확인할 수 있는 새로운 현장 진단 검사를, 단 15분 만에 실시할 수 있다고 발표했습니다. 또한, 암 진단을 위한 기술적으로 선진적인 신제품의 개발이 시장 성장을 뒷받침할 것으로 예측됩니다. 2021년 11월, 지멘스 헬스인어즈는 해상도가 향상되고 초고해상도 스캔 시 방사선 피폭량을 최대 45%까지 줄인 세계 최초의 광자 계수식 CT 스캐너 ‘Naeotom Alpha'를 발매했습니다. 따라서, 앞서 언급한 요인들로 인해 이 부문은 가까운 시일 내에 성장을 보일 것으로 예측됩니다.
또한, 정부와 기타 의료 기관들은 50세에서 75세 사이의 여성들에게 유방촬영술 검진을 받을 수 있는 기회를 제공하는 노력을 기울이고 있습니다. 2020년 6월, 미국의 의료기기 제조업체인 후지필름 메디컬 시스템즈는 미국 내 유방암 조기 발견에 초점을 맞춘 새로운 검진 홍보 캠페인을 발표했습니다. “Aspire to Be Fearless"라는 제목의 이번 캠페인에서는 후지필름의 메시지를 널리 알리기 위해 이동식 유방촬영 차량이 미국 전역을 순회합니다. 이 차량에는 대기실, 탈의실, 그리고 후지필름의 최신 유방 영상 진단 솔루션이 탑재되어 있습니다.
본 조사의 주요 특징:
- 본 보고서는 전 세계 암 진단 시장에 대한 상세한 분석을 제공하는 한편, 2025년을 기준 연도로 하여 2026년부터 2033년까지의 예측 기간 동안 시장 규모 및 연평균 성장률(CAGR)을 제시하고 있습니다. 또한, 다양한 부문에서 잠재적인 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 시장 성장 억제요인, 기회, 신규 검사의 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 보고서에서는 다음의 주요 항목(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)을 바탕으로 전 세계 암 진단 시장의 주요 기업 프로파일을 소개했습니다.
- 세계 암 진단 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 세계 암 진단 시장 분석에 사용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 암 진단 시장 : 테스트 유형별, 2021년-2033년
제5장 세계의 암 진단 시장 : 암 유형별 2021년-2033년
제6장 세계의 암 진단 시장 : 최종사용자별 2021년-2033년
제7장 세계의 암 진단 시장 : 지역별, 2021년-2033년
제8장 경쟁 구도
제9장 섹션
LSH 26.07.10Cancer Diagnostics Market is estimated to be valued at USD 77.95 Bn in 2026 and is expected to reach USD 149.97 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 77.95 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.80% | 2033 Value Projection: | USD 149.97 Bn |
Cancer is a large group of diseases that can start in almost any organ or tissue of the body when abnormal cells grow uncontrollably, go beyond their usual boundaries to invade adjoining parts of the body, and/or spread to other organs. The latter process is called metastasizing and is a major cause of death from cancer. A neoplasm and malignant tumor are other common names for cancer. Tumor biomarkers test used in the diagnosis of cancer include, prostate-specific antigen (PSA), circulating tumor cells (CTC), Alfa-fetoprotein test (AFP), CA-19 test for pancreatic cancer, HER-2 test, BRCA test, ALK test for lung cancer, carcinoembryonic test (CEA), EGFR mutation test, and RAS mutation test.
Market Dynamics
The key market players are focusing on the adoption of growth organic strategies such as launching new cancer diagnostics, which is attributed to the growth of the global cancer diagnostics market. For instance, in March 2020, BD (Becton, Dickinson and Company) a medical technology company, and BioMedomics, a privately held, U.S.-based clinical diagnostics company, announced the release of a new point-of-care test that can detect antibodies in blood to confirm current or past exposure to PARP biomarker test in as little as 15 minutes. Furthermore, the development of new technologically advanced products for cancer diagnosis is expected to support market growth. In November 2021, Siemens Healthineers launched Naeotom Alpha, the globe's first photon-counting CT Scannerwith improved resolution as well as a reduction in radiation dose by up to 45% for ultra-high resolution scans. Thus, the segment is expected to show growth in the near future due to the above-mentioned factors.
Furthermore, governments and other healthcare organizations are taking initiatives to provide women between 50 to 75 years access to mammography screening. In June 2020, Fujifilm Medical Systems is Medical equipment manufacturer in the U.S.A. announced a new breast cancer screening awareness campaign focused on early detection of the disease in the United States. The 'Aspire to Be Fearless' campaign involves a mobile mammography vehicle traveling throughout the United States to spread Fujifilm's message. The vehicle includes a waiting room, dressing room, and the latest breast imaging solutions from Fujifilm.
Key features of the study:
- This report provides an in-depth analysis of the global cancer diagnostics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period 2026-2033, considering 2025 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new test launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global cancer diagnostics market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratories, Inc., and BPS Bioscience, Inc. Antibodies Inc., Networks LLC, Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH, Bio Rad Laboratories Inc., Exagen Inc., Genway Biotech, Inc., Microdrop LLC (imaware), Svar Life Science AB, Abbott Laboratories, Thermo Fisher Scientific Inc., Bio Rad Laboratories Inc., GE Healthcare, Illumina, Inc., Koninklijke Philips N.V., Toshiba Medical Systems Corporation, Agilent Technologies, Inc., Aurora Imaging Technologies, Inc., and Quest Diagnostics.
- Global cancer diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer diagnostics market.
Detailed Segmentation:
- Global Cancer Diagnostics Market, By Test Type (Revenue, USD Bn, 2021 - 2033)
- PSA Tests
- CTC Tests
- AFP Tests
- CA-19 Tests
- HER2 Tests
- BRCA Tests
- ALK Tests
- CEA Tests
- EGFR Mutation Tests
- KRAS Mutation Tests
- Others
- Ultrasound
- Mammography
- MRI Scan
- PET Scan
- CT Scan
- Needle Biopsy
- Endoscopic Biopsy
- Bone Marrow Biopsy
- Others
- Tumor Biomarkers Tests
- Imaging
- Biopsy
- Liquid Biopsy
- Immunohistochemistry
- In Situ Hybridization
- Global Cancer Diagnostics Market, By Cancer Type (Revenue, USD Bn, 2021 - 2033)
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Melanoma
- Blood Cancers
- Prostate Cancer
- Ovarian Cancer
- Stomach Cancer
- Liver Cancer
- Others
- Global Cancer Diagnostics Market, By End User (Revenue, USD Bn, 2021 - 2033)
- Hospital Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Others
- Global Cancer Diagnostics, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Myriad Genetics, Inc
- F. Hoffmann-La Roche AG
- Invitae Corporation
- NeoGenomics Laboratories, Inc.
- BPS Bioscience, Inc.
- Antibodies Inc.
- Networks LLC
- Beckman Coulter, Inc.
- Euro Diagnostica AB
- F. Hoffmann-La Roche Ltd.
- Qiagen NV
- Siemens Healthcare GmbH
- Bio Rad Laboratories Inc.
- Exagen Inc.
- Genway Biotech, Inc.
- Microdrop LLC (imaware)
- Svar Life Science AB
- Thermo Fisher Scientific Inc.
- Bio Rad Laboratories Inc.
- GE Healthcare
- Illumina, Inc.
- Koninklijke Philips N.V.
- Toshiba Medical Systems Corporation
- Agilent Technologies, Inc.
- Aurora Imaging Technologies, Inc.
- Quest Diagnostics.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Test Type
- Market Snippet, By Cancer Type
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaboration
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Cancer Diagnostics Market, By Test Type, 2021 - 2033 (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Tumor Biomarkers Tests
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- PSA Tests
- CTC Tests
- AFP Tests
- CA-19 Tests
- HER2 Tests
- BRCA Tests
- ALK Tests
- CEA Tests
- EGFR Mutation Tests
- KRAS Mutation Tests
- Others
- Imaging
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Ultrasound
- Mammography
- MRI Scan
- PET Scan
- CT Scan
- Biopsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Needle Biopsy
- Endoscopic Biopsy
- Bone Marrow Biopsy
- Others
- Liquid Biopsy
- Immunohistochemistry
- In Situ Hybridization
5. Global Cancer Diagnostics Market, By Cancer Type 2021 - 2033 (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Blood Cancers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Ovarian Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Stomach Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Liver Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
6. Global Cancer Diagnostics Market, By End User 2021 - 2033 (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Associated Labs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Independent Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Diagnostic Imaging Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Cancer Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
7. Global Cancer Diagnostics Market, By Regions, 2021 - 2033 (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, By Test Type, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Cancer Type, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, By Test Type, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Cancer Type, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Test Type, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Cancer Type, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, By Test Type, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Cancer Type, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, By Test Type, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Cancer Type, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Test Type, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Cancer Type, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021 - 2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Myriad Genetics, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Invitae Corporation
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- NeoGenomics Laboratories, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- BPS Bioscience
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Antibodies Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Networks LLC
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Beckman Coulter, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Euro Diagnostica AB
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- F.Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Qiagen NV
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Siemens Healthcare GmbH
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Augurex Life Sciences Corp.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Thermo Fisher Scientific Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bio Rad Laboratories Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Exagen Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Genway Biotech, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Microdrop LLC (imaware)
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Svar Life Science AB
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Thermo Fisher Scientific Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bio Rad Laboratories Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- GE Healthcare
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Illumina, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Koninklijke Philips N.V.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Toshiba Medical Systems Corporation
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Agilent Technologies, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Aurora Imaging Technologies, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Quest Diagnostics.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Myriad Genetics, Inc.
9. Section
- References
- Research Methodology
- About us and Sales Contact
